Sarepta Therapeutics(SRPT)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

SRPT Sarepta Therapeutics

已收盘 05-07 16:00:00 EDT

136.04

+1.00

+0.74%

盘后136.30

+0.26+0.19%

19:59 EDT

最高146.68	最低132.30	成交量200.33万
今开135.10	昨收135.04	日振幅10.65%
总市值128.59亿	流通市值122.92亿	总股本9,452万
成交额2.76亿	换手率2.22%	流通股本9,036万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"SRPT","market":"US","secType":"STK","nameCN":"Sarepta Therapeutics","latestPrice":136.04,"timestamp":1715112000000,"preClose":135.04,"halted":0,"volume":2003304,"hourTrading":{"tag":"盘后","latestPrice":136.3,"preClose":136.04,"latestTime":"19:59 EDT","volume":42806,"amount":5824150.5224,"timestamp":1715126395535},"delay":0,"floatShares":90357375,"shares":94523766,"eps":0.180044,"marketStatus":"已收盘","marketStatusCode":5,"change":1,"latestTime":"05-07 16:00:00 EDT","open":135.1,"high":146.68,"low":132.3,"amount":275813832.96888,"amplitude":0.106487,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.180044,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1715155200000},"adr":0,"listingDate":865396800000,"adjPreClose":135.04,"adrRate":0,"preHourTrading":{"tag":"盘前","latestPrice":134.5,"preClose":135.04,"latestTime":"09:21 EDT","volume":25,"amount":3365.2000000000003,"timestamp":1715088110687},"postHourTrading":{"tag":"盘后","latestPrice":136.3,"preClose":136.04,"latestTime":"19:59 EDT","volume":42806,"amount":5824150.5224,"timestamp":1715126395535},"volumeRatio":1.533356},"requestUrl":"/m/hq/s/SRPT","defaultTab":"news","newsList":[{"id":"2433276434","title":"Sarepta Therapeutics, Inc.2024财年第一财季实现净利润36.12百万美元，同比增加106.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=2433276434","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2433276434?lang=zh_cn&edition=full","pubTime":"2024-05-06 00:25","pubTimestamp":1714926301,"startTime":"0","endTime":"0","summary":"3月31日，Sarepta Therapeutics, Inc.公布财报，公告显示公司2024财年第一财季净利润为36.12百万美元，同比增加106.99%；其中营业收入为4.13亿美元，同比增加62.60%，每股基本收益为0.38美元。从资产负债表来看，Sarepta Therapeutics, Inc.总负债22.63亿美元，其中短期债务1.06亿美元，资产负债比为1.43，流动比率为4.05。机构评级：截至2024年3月31日，当前有19家机构对Sarepta Therapeutics, Inc.目标价做出预测，其中目标均价为166.89美元，其中最低目标价为128.00美元，最高目标价为224.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050600250487d52c4f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050600250487d52c4f&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2432635946","title":"美国研究综述-Paramount Global、Sprout Social、Williams-Sonoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2432635946","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2432635946?lang=zh_cn&edition=full","pubTime":"2024-05-03 15:04","pubTimestamp":1714719854,"startTime":"0","endTime":"0","summary":"    路透5月3日 - 华尔街证券分析师周五调整了对派拉蒙全球公司、Sprout Social 和 Williams-Sonoma 等几家美国上市公司的评级和目标价。* Paramount Global   ：Seaport Research Partners将其评级从 \"买入 \"下调至 \"中性\"。* Williams-Sonoma Inc   ：摩根大通将其评级从 \"减持 \"上调至 \"中性\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2432298261","title":"坎托菲茨杰拉德公司：重申Sarepta Therapeutics(SRPT.US)评级，由中性调整至中性评级, 目标价128.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2432298261","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2432298261?lang=zh_cn&edition=full","pubTime":"2024-05-03 00:25","pubTimestamp":1714667111,"startTime":"0","endTime":"0","summary":"坎托菲茨杰拉德公司：重申Sarepta Therapeutics(SRPT.US)评级，由中性调整至中性评级, 目标价128.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050300251487cb8791&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050300251487cb8791&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2432601002","title":"BUZZ-Sarepta 第一季度营收超预期后上涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2432601002","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2432601002?lang=zh_cn&edition=full","pubTime":"2024-05-02 21:49","pubTimestamp":1714657754,"startTime":"0","endTime":"0","summary":"    5月2日 - ** Sarepta Therapeutics公司  股价上涨7%，达到两个月来的最高点140.10美元。** 该公司周三公布的  第一季度营收为 4.135 亿美元，预计为 3.778 亿美元 - LSEG** 公司表示，在监管机构决定扩大该疗法的患者范围之前，美国食品及药物管理局将比之前预计的更早向公司提供其基因疗法Elevidys的标签草案，该疗法用于治疗一种肌肉萎缩疾病。** FDA对Elevidys的目标行动日期是6月21日** 经纪公司 BMO Capital Markets 认为，FDA 对 Elevidys 的决定 \"很可能在 6 月初公布\"。** 年初至今，股价上涨了 47.1%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2432160967","title":"Sarepta Therapeutics, Inc.盘中异动 早盘大幅拉升8.10%报141.50美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2432160967","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2432160967?lang=zh_cn&edition=full","pubTime":"2024-05-02 21:32","pubTimestamp":1714656731,"startTime":"0","endTime":"0","summary":"北京时间2024年05月02日21时32分，Sarepta Therapeutics, Inc.股票出现波动，股价快速拉升8.10%。Sarepta Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.24%。其相关个股中，Allarity Therapeutics, Inc.、Context Therapeutics Inc.、Aptevo Therapeutics Inc.涨幅较大，Allarity Therapeutics, Inc.、Aptevo Therapeutics Inc.、Context Therapeutics Inc.较为活跃，换手率分别为1438.68%、301.14%、82.61%，振幅较大的相关个股有Allarity Therapeutics, Inc.、Zura Bio Limited C/Wts 、Aptevo Therapeutics Inc.，振幅分别为30.66%、22.07%、11.47%。Sarepta Therapeutics, Inc.公司简介：Sarepta Therapeutics公司是一家专注于治疗罕见、传染病和其他疾病的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405022132118b6d288c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405022132118b6d288c&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2416909567","title":"Sarepta Therapeutics, Inc.2023财年实现净利润-5.36亿美元，同比增加23.76%","url":"https://stock-news.laohu8.com/highlight/detail?id=2416909567","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2416909567?lang=zh_cn&edition=full","pubTime":"2024-03-04 00:27","pubTimestamp":1709483234,"startTime":"0","endTime":"0","summary":"12月31日，Sarepta Therapeutics, Inc.公布财报，公告显示公司2023财年净利润为-5.36亿美元，同比增加23.76%；其中营业收入为12.43亿美元，同比增加33.23%，每股基本收益为-5.80美元。机构评级：截至2023年12月31日，当前有21家机构对Sarepta Therapeutics, Inc.目标价做出预测，其中目标均价为164.42美元，其中最低目标价为128.00美元，最高目标价为224.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024030400272887e0e75a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024030400272887e0e75a&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2415056730","title":"美国研究综述-Okta、Salesforce、Sarepta Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2415056730","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2415056730?lang=zh_cn&edition=full","pubTime":"2024-02-29 15:07","pubTimestamp":1709190420,"startTime":"0","endTime":"0","summary":"    路透社2月29日 - 华尔街证券分析师周四调整了对几家美国上市公司的评级和目标价，其中包括 Okta、Salesforce 和 Sarepta Therapeutics。要点             * Clearwater Analytics Holdings Inc   ：摩根大通将其评级从 \"增持 \"下调至 \"中性             * Okta Inc   ：Piper Sandler将目标价从85美元上调至110美元              * Salesforce Inc   ：巴克莱将目标价从325美元上调至355美元              * Sarepta Therapeutics Inc   ：Leerink Partners将目标价从145美元上调至165美元              * Universal Health Services Inc   ：Leerink Partners将目标价从174美元上调至192美元  以下是路透社周四报道的美国公司研究行动摘要。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2412972660","title":"美国研究综述-欧特克、Hireright Holdings、斑马技术公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2412972660","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2412972660?lang=zh_cn&edition=full","pubTime":"2024-02-19 14:40","pubTimestamp":1708324852,"startTime":"0","endTime":"0","summary":"    路透社2月19日 - 华尔街证券分析师周一调整了对几家美国上市公司的评级和目标价，其中包括 Autodesk、Hireright Holdings 和斑马技术公司。要闻             * 欧特克公司  ：贝伦贝格将目标价从250美元上调至290美元              * Hireright Holdings Corp   ：Needham将目标价从 \"买入 \"下调至 \"持有              * 斑马技术公司  ：Baird将目标价从292美元上调至312美元  以下是路透社周一报道的美国公司研究报告摘要。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2411566281","title":"嗡嗡声--美国股票走势-Super Micro Computer、Kinsale Capital、Kinnate Biopharma","url":"https://stock-news.laohu8.com/highlight/detail?id=2411566281","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2411566281?lang=zh_cn&edition=full","pubTime":"2024-02-16 23:53","pubTimestamp":1708098808,"startTime":"0","endTime":"0","summary":"        *      个股异动的 Eikon 搜索字符串：[STXBZ］        *      The Day Ahead 新闻通讯：          *      The Morning News Call时事通讯：      2月16日 - 周五，华尔街主要股指走低，此前一份热度高于预期的生产者物价报告打压了市场对美国联邦储备委员会  即将降息的猜测。美东时间10:31，道琼斯工业平均指数  下跌0.27%，报38,669.2点。标准普尔500指数  下跌0.39%，报5,010.17点；纳斯达克综合指数  下跌0.75%，报15,787.267点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2411322694","title":"美国研究综述-布鲁克公司、Cymabay Therapeutics、SSR 矿业公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2411322694","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2411322694?lang=zh_cn&edition=full","pubTime":"2024-02-14 15:35","pubTimestamp":1707896137,"startTime":"0","endTime":"0","summary":"    路透社2月14日 - 华尔街证券分析师周三调整了对布鲁克公司、Cymabay Therapeutics 和 SSR 矿业公司等几家美国上市公司的评级和目标价。要点             * 布鲁克公司  ：摩根大通将其评级从中性上调至增持             * Cymabay Therapeutics Inc   ：Piper Sandler将其评级从 \"增持 \"下调至 \"中性\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sarepta.com","stockEarnings":[{"period":"1week","weight":0.0484},{"period":"1month","weight":0.0711},{"period":"3month","weight":0.0683},{"period":"6month","weight":0.6736},{"period":"1year","weight":0.0308},{"period":"ytd","weight":0.4004}],"compareEarnings":[{"period":"1week","weight":0.0128},{"period":"1month","weight":-0.0036},{"period":"3month","weight":0.0457},{"period":"6month","weight":0.1814},{"period":"1year","weight":0.2519},{"period":"ytd","weight":0.0868}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Sarepta Therapeutics, Inc.于1980年7月22日在俄勒冈州注册成立。该公司是一家商业阶段的生物制药公司，专注于通过发现和开发独特的RNA靶向疗法、基因疗法和其他用于治疗罕见疾病的基因治疗模式来帮助患者。应用他们的专有、高度差异化和创新技术，并通过与战略合作伙伴的合作，该公司开发了多个获批产品，用于治疗杜氏肌营养不良症，并正在为广泛的疾病和紊乱开发潜在的候选治疗药物，包括杜氏、肢带型肌营养不良症和其他与神经肌肉和中枢神经系统相关的疾病。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.050901},{"month":2,"riseRate":0.666667,"avgChangeRate":0.055118},{"month":3,"riseRate":0.5,"avgChangeRate":0.024789},{"month":4,"riseRate":0.333333,"avgChangeRate":0.013657},{"month":5,"riseRate":0.75,"avgChangeRate":0.180366},{"month":6,"riseRate":0.727273,"avgChangeRate":0.088071},{"month":7,"riseRate":0.363636,"avgChangeRate":0.007489},{"month":8,"riseRate":0.75,"avgChangeRate":0.094027},{"month":9,"riseRate":0.583333,"avgChangeRate":0.152276},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.101643},{"month":11,"riseRate":0.75,"avgChangeRate":0.091344},{"month":12,"riseRate":0.583333,"avgChangeRate":0.019375}],"exchange":"NASDAQ","name":"Sarepta Therapeutics","nameEN":"Sarepta Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Sarepta Therapeutics(SRPT)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Sarepta Therapeutics(SRPT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Sarepta Therapeutics,SRPT,Sarepta Therapeutics股票,Sarepta Therapeutics股票老虎,Sarepta Therapeutics股票老虎国际,Sarepta Therapeutics行情,Sarepta Therapeutics股票行情,Sarepta Therapeutics股价,Sarepta Therapeutics股市,Sarepta Therapeutics股票价格,Sarepta Therapeutics股票交易,Sarepta Therapeutics股票购买,Sarepta Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Sarepta Therapeutics(SRPT)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Sarepta Therapeutics(SRPT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}